key: cord-0865118-4unn3fmu
authors: Natarajan, Aravind; Zlitni, Soumaya; Brooks, Erin F.; Vance, Summer E.; Dahlen, Alex; Hedlin, Haley; Park, Ryan M.; Han, Alvin; Schmidtke, Danica T.; Verma, Renu; Jacobson, Karen B.; Parsonnet, Julie; Bonilla, Hector F.; Singh, Upinder; Pinsky, Benjamin A.; Andrews, Jason R.; Jagannathan, Prasanna; Bhatt, Ami S.
title: Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection
date: 2022-04-13
journal: Med (N Y)
DOI: 10.1016/j.medj.2022.04.001
sha: 1fa4b4fa033f6743e4567fd773d875433e491b77
doc_id: 865118
cord_uid: 4unn3fmu

Background COVID-19 manifests with respiratory, systemic, and gastrointestinal (GI) symptoms.1,2 SARS-CoV-2 RNA is detected in respiratory and fecal samples, and recent reports demonstrate viral replication in both the lung and intestinal tissue.3–5 Although much is known about early fecal RNA shedding, little is known about the long term shedding, especially in those with mild COVID-19. Furthermore, most reports of fecal RNA shedding do not correlate these findings with GI symptoms.6 Methods We analyze the dynamics of fecal RNA shedding up to 10 months after COVID-19 diagnosis in 113 individuals with mild to moderate disease. We also correlate shedding with disease symptoms. Findings Fecal SARS-CoV-2 RNA is detected in 49.2% [95% Confidence interval = 38.2%-60.3%] of participants within the first week after diagnosis. Whereas there was no ongoing oropharyngeal SARS-CoV-2 RNA shedding in subjects at and after 4 months, 12.7% [8.5%-18.4%] of participants continued to shed SARS-CoV-2 RNA in the feces at 4 months after diagnosis and 3.8% [2.0%-7.3%] shed at 7 months. Finally, we find that GI symptoms (abdominal pain, nausea, vomiting) are associated with fecal shedding of SARS-CoV-2 RNA. Conclusions The extended presence of viral RNA in feces, but not respiratory samples, along with the association of fecal viral RNA shedding with GI symptoms suggest that SARS-CoV-2 infects the GI tract, and that this infection can be prolonged in a subset of individuals with COVID-19.

technical duplicate, using RT-qPCR. We also assayed 278 of the 673 RNA samples derived 193 predominantly from samples collected in the first month of the study for the N1 and E gene using 194 multiplexed droplet digital PCR (ddPCR) assays, since ddPCR is more robust to the presence of 195 inhibitors of PCR than RT-qPCR 39 . We found the measurement of the N1 and E genes using 196 ddPCR to be concordant with one another (Figure S2 ), and thus assayed the remainder of the 197 samples (n = 395) only for the N1 gene. In total, 5,384 RT-qPCR assays and 951 ddPCR assays 198 measuring the concentration of fecal SARS-CoV-2 gRNA were carried out. This dataset was 199 then analyzed as summarized in the STAR methods. SARS-CoV-2 viral RNA concentrations 200 estimated by RT-qPCR and ddPCR targeting the N1 gene are found to be concordant ( Figure S3 ; 201 ZY, Pearson's correlation, R = 0.98, P < 0.0001; OG, Pearson's correlation, R = 0.9, P < 202 0.0001). Given the relative concordance between the RT-qPCR and ddPCR results, and the fact 203 that that we have a richer data set across four target genes in duplicate reactions using 204 we decided to carry out the rest of our analyses on the RT-qPCR results, alone; where relevant, 205 associated analyses using ddPCR derived viral RNA concentrations are included in Data S1 and 206 are referenced below. We applied a logistic regression model that averaged RT-qPCR derived 207 viral RNA concentrations over all four target genes and both sample collection kits with fixed 208 effects to correct for systematic differences. The model uses a generalized estimating equations 209 (GEE) approach and is described in the methods; it was used in all our primary analyses except 210 where noted. 211 212 J o u r n a l P r e -p r o o f

In study participants with uncomplicated COVID-19, the GEE model that considers qPCR derived viral RNA concentrations across all four target genes in the gRNA shows that 214 49% [95% Confidence interval = 38 -60%] of participants (n = 102) were positive for fecal 215 SARS-CoV-2 RNA at the first time point around day 3 (Fig. 2A) . The proportion of participants 216 with fecal shedding of SARS-CoV-2 RNA gradually declined to 40% (95% Confidence interval 217 = 28 -53%, n = 86) on day 14 and 11.0% (6 -20%, 83) on day 28. To determine whether fecal 218 SARS-CoV-2 RNA shedding continues after oropharyngeal shedding ceases, we then compared 219 the presence of SARS-CoV-2 RNA in fecal samples to that in OP samples from the same 220 participant 36 . At four months (120 days) post-enrollment, all participants (n = 57) who provided 221

paired fecal and OP samples tested negative for SARS-CoV-2 RNA in their OP samples, but 222 12.7% [95% Confidence interval = 8.5% -18.4%] of their fecal samples were positive for SARS-223

CoV-2 RNA (Fig. 2B) . OP We then calculated the absolute concentrations of fecal SARS-CoV-2 RNA using RT-231 qPCR of samples collected in the ZY kit ( Fig. 2C ; corresponding data from samples collected in 232 the OG kit are presented in Figure S4 ). In samples collected around day 3, between 54 -77 % of 233 the participants shed viral RNA in their stool, depending on the gene targeted in the assay. At the 234 first time point, looking at viral RNA concentrations derived from measuring the N1 gene, the 235 gene that yielded the most number of SARS-CoV-2 positive fecal samples at this time point, we 236 find that positive stool samples have between 0.32 to 3.97 log10 copies of viral RNA per µL of 237 eluate. We find that these viral RNA concentration data are concordant when measured using an 238 orthogonal assay using ddPCR ( Figure S5 ). Finally, to understand the temporal dynamics of 239 shedding, we treat time since enrollment in study as a continuous variable (Fig. 2D) although there is ongoing debate about its specificity. Hence, we next quantified sgRNA 40 

As samples from this study were collected from individuals on a randomized controlled 258 trial of Peginterferon-lambda, we carried out an exploratory analysis to determine whether this 259 intervention affected fecal SARS-CoV-2 RNA clearance in the first month after treatment. We 260 find that there is no significant difference in the percentage of participants who shed SARS-CoV-261 2 RNA in their feces between the two arms of the study at the first three time points (Fig. 3A) . 262

We went on to calculate the odds ratio adjusted for age, sex, collection kit type and target gene 263 (adjusted odds ratio, aOR) that a person who received the IFN-λ intervention would also be 264 shedding viral RNA in stool at the first three time points (Fig. 3B) . At the first time point, around 265 3 days after enrollment in the study, we find that receiving the IFN-λ intervention is associated 266 with lower odds of shedding viral RNA in stool (aOR = 0.32, 95% Confidence interval = 0.12 -267 0.89). While the association between exposure to IFN-λ and lower odds of fecal viral RNA 268 shedding is intriguing and suggests that exposure to the intervention on day 1 may decrease 269 short-term fecal viral RNA shedding, this association failed to replicate upon execution of 270 several sensitivity analyses ( Figure S7 ; Data S1). In summary, in the current study we do not 271 observe a robust effect of a single 180 mcg subcutaneous dose of IFN-λ on fecal SARS-CoV-2 272 RNA shedding. 273 274 Subjects with detectable fecal SARS-CoV-2 RNA also manifest gastrointestinal symptoms 275

In limited recent studies, the presence of fecal SARS-CoV-2 RNA has been linked to the 276 presence of GI symptoms. However, these studies are mostly cross-sectional in nature, collect 277 symptomatology data retrospectively and do not use a uniform, benchmarked methodology for 278 J o u r n a l P r e -p r o o f quantification of SARS-CoV-2 RNA in stool. To address the question of whether fecal viral 279 RNA shedding is associated with GI symptoms, we collected comprehensive longitudinal 280 symptomatology data, including information on GI symptoms, from study participants in this 281 interventional trial and compared these to absolute viral RNA concentrations measured in their 282 feces (Fig. 4A) . Across the first month of the study, we find that participants who shed viral 283 RNA in their stool were more likely to report nausea (aOR = 1.61, 95% Confidence interval = 284 To determine whether the observed association between symptoms and fecal shedding 293 was independent of respiratory shedding, we next divided the data into two subsets, based on 294 whether or not the participant was shedding virus in the oropharynx at the time the fecal sample 295 was taken; specifically, we looked at participants whose OP swabs collected within 3 days of the 296 stool sample (a) did not have any detectable SARS-CoV-2 RNA (n = 69; Fig. 4B ), or (b) had 297 detectable SARS-CoV-2 RNA (n = 54; Fig. 4C ). Participants who were shedding viral RNA 298 from the oropharynx had higher rates of almost all of COVID-19-related symptoms, and we 299 found no significant association between fecal shedding and symptoms for this subgroup. By 300 contrast, participants who were not shedding viral RNA from the oropharynx had far lower rates 301 J o u r n a l P r e -p r o o f of COVID-19-related symptoms in general, but we found many significant associations between 302 fecal shedding and symptoms for this subgroup. This is consistent with an interpretation where 303 patients with an active infection of the respiratory system experience an array of COVID-19-304 related symptoms independent of whether or not they are fecal shedding, but where patients 305 whose respiratory infection has cleared could still be experiencing an active infection of the GI 306 tract, which itself is associated many different COVID-19-related symptoms. Taken together, 307 these data suggest that fecal shedding of SARS-CoV-2 RNA is a possible indicator of an 308 ongoing GI infection, and that this infection is accompanied by GI and other systemic symptoms. 309 J o u r n a l P r e -p r o o f

Severe SARS-CoV-2 infections can lead to a life-threatening hypoxemic respiratory 311 failure. Therefore, much of the initial investigation of COVID-19 focused on the respiratory 312 infection and related manifestations of the disease. This may be why, two years into the 313 pandemic, we still do not definitively know whether SARS-CoV-2 infects the GI tract of 314 humans. However, we know that SARS-CoV-2 can infect intestinal cells in vitro -both in cell 315 lines 33 and human tissue-derived intestinal organoids. 30 that only a subset of individuals with COVID-19 exhibited fecal viral RNA shedding may be the 335 consequence of a broad, nearly one week, window for the first sample collection from the time of 336 diagnosis; alternatively, this may also be the result of physiological and genetic differences 337 between individuals. Over the course of the first month in this study, the number of participants 338

shedding fecal viral RNA decreased to 11% [6 -20%] , and the viral RNA concentration among 339 those still shedding decreased from up to ~3 log10 copies per µL to < 1 log10 copies per µL. At 340 the first time point, we find that a larger proportion of participants shed viral RNA in their OP 341 swab compared to their feces; however, this trend reverses in the rest of the time points. This 342 suggests that clearance of SARS-CoV-2 is more rapid in the respiratory tissue than it is in the GI 343 tissue and that the GI tract may be a site of longer term infection. being considered for use in guiding community level policies (e.g. shutdowns and reopenings), 43-363 47 it is critical that we understand how respiratory viral shedding and transmissibility of SARS-364

CoV-2 RNA are temporally related to fecal viral RNA shedding. 365 366 Based on the available evidence, it is highly plausible that the presence of GI symptoms 367 in patients with COVID-19 is due to infection of the GI tissues. With a comprehensive collection 368 of clinical symptom data and fecal viral RNA concentrations, we find that over the course of the 369 first month after enrollment, those who shed viral RNA in stool are more likely to also have GI 370 symptoms including nausea, vomiting and abdominal pain among other symptoms like runny 371 nose, body aches and headaches. It is notable that those who shed viral RNA in stool were not 372 more likely to have diarrhea -this finding is contradicted by two prior studies (n = 59, 44) that 373 found that patients with diarrhea were more likely to shed viral RNA in stool and, that too, at 374 higher concentrations. 3 Our finding of no association between diarrhea and fecal viral RNA 375 shedding might be due to the relatively small number of participants who reported diarrhea in 376 our study. When focusing on participants who had extended shedding of viral RNA in their stool 377 J o u r n a l P r e -p r o o f even after their OP shedding had ceased, we found that fecal shedding of viral RNA is associated 378 with a range of systemic and GI symptoms. On the other hand, for the duration that participants 379 provided an OP swab positive for viral RNA i.e. had an active respiratory infection, we do not 380 find any association between fecal viral RNA shedding and symptomatology. We postulate that 381 this is because participants who have an ongoing respiratory infection manifest classic COVID-382 19 related symptoms, whether or not they have an infection in their GI tract. These observations 383 support the hypothesis that there is likely a prolonged SARS-CoV-2 infection of the GI tract 384 even after the upper respiratory infection is cleared. Since the GI tract is a highly immunoactive 385 tissue, 48 Despite its large size and longitudinal nature, this study has limitations. First, the study is 406 limited in its resolution, having only collected six samples over a 10-month period. Follow up 407 studies with more frequent sampling, especially in the first two months after diagnosis, may 408 allow a more nuanced model of decline of fecal viral RNA concentration. This will also allow a 409 closer evaluation of the relative cessation of viral RNA in stool vis-a-vis other respiratory 410 samples such as the OP swab. We were also unable to collect stool samples in a way that would 411 enable recovery of live virus. As this was an outpatient study during the early part of the 412 pandemic, we required participants to collect stool themselves at home, and then mail the stool 413 kits to us. For safety and practical purposes, we thus had to provide participants with kits that 414 were rated for virus inactivation. Future studies, which facilitate the careful, consistent collection 415 of stool samples from individuals with COVID-19 in a safe setting, might enhance the likelihood 416 of more accurate measurement of live virus. This would be more direct evidence of SARS-CoV-417 2 being viable in the gut. Third, we did not obtain direct tissue evidence of infection -to do so 418 would require intestinal biopsies. Of note, recent autopsy 5 and prior biopsy-based 22 The primary results of the null study, secondary outcomes, and the full details of study 477 recruitment, inclusion and exclusion criteria were previously reported on and are only briefly 478 summarized here. 36 Individuals with study defined lab abnormalities, respiratory rate >20 breaths 479 per minute, room air oxygen saturation levels <94%, pregnancy or breastfeeding, or recent 480 history of hospitalization, uncontrolled liver disease, or use of COVID-19 interventional 481 therapeutics, anticoagulants, antibiotics, and/or antivirals were excluded from the study. Subjects 482 were randomized 1:1 to either the interventional or control study arm to receive a one-time 483 subcutaneous injection of Peginterferon Lambda-1a or saline, respectively, on the first day of 484 enrollment. Randomization was stratified by age (≥ 50 and < 50 years old) and sex. The 485 demographics of study participants are summarized in Table 1 For the first 28 days following enrollment, participants in the clinical trial completed 500 daily symptom questionnaires administered via REDCap Cloud (version 1.5) 36 and self-501 performed daily measurements of temperature and oxygen saturation using study provided at-502 home devices. Participants returned to the study site on 1, 3, 5, 7, 10, 14, 21, 28 days (all +/-1 503 day) and 120, 210, and 300 days (all +/-3 weeks) post-enrollment for follow-up visits during 504 which oropharyngeal (OP) swabs were collected, symptoms were queried, and vital signs were 505 recorded. All clinical trial participants were provided a fecal sample collection kit on 0, 5, 21, 28, 506 120, and 210 days after enrollment and were asked to collect a stool sample in the provided kit, 507 store at room temperature, and drop off for processing at their subsequent study visit or mail 508 back to the study site at the long term follow up time points. We define the following six time 509 points based on when participants returned the stool samples: days 3 (range 0 -7 days), 14 (8 -510 21), 28 (22 -35) , 120 (75 -165), 210 (166 -255) and 300 (>255) (Fig. 1A) . RNA standards, or nuclease free water using a Biomek-FX liquid handler. Every assay plate also 575 included standard curves. Standard curves were prepared by serially diluting quantitative 576 synthetic SARS-CoV-2 RNA from 10 5 -10 -1 copies per µL. For standard curves in the sgRNA 577 assays, a purified PCR product corresponding to the target gene 40 was diluted from 10 6 -10 -1 578 copies per reaction. Nuclease-free water was used as a negative control. previously published companion study. 36 This study measured the E gene in the SARS-CoV-2 604 genomic RNA and RNaseP in the human genome in a multiplexed assay. RNaseP was used as an 605 internal control for the extraction of RNA and to monitor the effect of RT-qPCR inhibitors in 606 these samples. Only samples where RNaseP was detected were evaluated. As a requirement for 607 the Stanford FDA Emergency Use Authorization for the SARS-CoV-2 RNA diagnostic test, the 608 sensitivity of the assay for nasopharyngeal swab testing was determined to be 1000 copies/mL. 609

While the FDA did not require the assessment of assay sensitivity for different respiratory 610 tissues, we believe that the assay sensitivity for nasopharyngeal vs. oropharyngeal swabs to be 611 comparable. Similarly, based on previously reported benchmarking and Limit of Detection 612 (LoD) assays, the sensitivity of fecal sample testing for SARS-CoV-2 RNA is 1000 613 copies/mL. 11 Moreover, the assay sensitivity of fecal testing was highly concordant between the 614 tested genes, particularly for the N1, N2, and E genes; RdRP has a slightly lower sensitivity by 615 comparison. 11 Therefore, we are confident that the sensitivity of SARS-CoV-2 RNA testing is 616 highly comparable in stool and respiratory biospecimen of the study subjects (1000 copies/mL). 617 618 ddPCR quantification of RNA: Droplet digital PCR (ddPCR) is resilient to PCR inhibitors 619 prevalent in stool, enables absolute quantification without the need for an exhaustive standard 620 curve, and is also more sensitive than traditional qPCR. 11,38 Therefore, we quantified viral RNA 621 using this orthogonal method as previously described. 11 The ddPCR reactions were prepared 622 with the One-Step RT-ddPCR Advanced Kit for Probes. Using a Biomek FX liquid handler, each 623 reaction well was loaded with 5.5 µL of extracted RNA to 5.5 µL Supermix, 2. The ddPCR analysis was guided by the Droplet Digital PCR Applications Guide on 637 QX200 machines (BioRad) 57 and the digital MIQE guidelines. 58 We have included the 638 recommended associated checklist in Data S1. We applied a rigorous strategy to threshold the 639 assays and identify true positive reactions as previously described 11 to quantify viral RNA, we took a conservative approach at every step to ensure high specificity. 654

First, we adopted a method to determine the limit of blank (LoB) that is based on guidelines set 655 out by the Clinical and Laboratory Standards Institute (CLSI) 63 , as summarized in the next 656 section. We systematically identified the LoB for stool collected in the OG and ZY kits against 657 each of the four target genes in independent combinations. All samples with an RNA 658 concentration equal to or lower than the corresponding LoB are considered to have an 659 undetermined amount of viral RNA, since this is below a reliable specificity threshold for that 660 assay (example in Data S1). Second, we identified the linear detection range of our assays. A six-661 point 10-fold dilution series of synthetic SARS-CoV-2 RNA from the American Type Culture 662 Collection (ATCC) starting at 10 4 log10 copies per µL was used here as previously described 11 . 663

Resulting standard curves generated for each of the genes in the genomic RNA measured using 664 RT-qPCR and those measured by ddPCR are shown in Data S1. In assays that detected sgRNA, 665 we used a six-point 10-fold dilution series with pre-quantified sgRNA starting at 10 6 log10 copies 666 per µL from a previously reported study 40 and provide standard curves in Data S1. All samples 667 that yield a viral RNA concentration below the lowest detectable concentration in the linear 668 range of standards are considered to have an undetermined amount of viral RNA. Third, 669

anticipating that few if any stool samples collected beyond the 28 day time point were going to 670 be positive for SARS-CoV-2 RNA, we incorporated a control to guard against false negatives 671 that could result from incomplete or inefficient extraction of RNA, as previously described 11 . 672

Briefly, all long-term stool samples were spiked with 10 The 64 RNA extracts were assayed for the E, N1, N2 and RdRP genes in the gRNA in duplicate 694 reactions identical to how clinical samples were assayed in this study. Next, these samples were 695 also assayed for the N1 genes in ddPCR assays. Taken together, we calculated the LoB for 696 relevant combinations of stool preservation (OG, ZY), target gene (E, N1, N2 and RdRP), and 697 detection method (RT-qPCR, ddPCR). 698 699 It was notable that across all targeted genes in both RT-qPCR and ddPCR assays, the LoB 700 measured in the OG kit was higher than that measured in the ZY kit. Specifically, RT-qPCR 701 assays targeting the N1 gene yielded 0.487 log10 copies per µL of viral RNA in samples 702 preserved in OG and 0.237 log10 copies per µL of RNA in those preserved in ZY. These 703 corresponded to 0.429 copies per µL and 0.164 copies per µL of RNA in ddPCR assays targeting 704 the N1 gene. Finally, while targeting the N2 gene via RT-qPCR also yielded low RNA 705 concentrations in these negative controls, E and RdRP were highly specific and yielded no 706 detectable RNA for these targets in the negative controls (Data S1). The RNA concentration 707 derived here is used as the LoB in all further data analysis. Thus, all samples that bear an RNA 708 concentration equal to or lower than the corresponding LoB are considered to have an 709 undetermined amount of viral RNA, since this is below a reliable specificity threshold for that 710 assay (example in Data S1). 711 712 Guarding against PCR inhibitors for the reliable detection of viral RNA: Aware of the presence 713 of potential PCR inhibitors in the stool matrix, we wanted to estimate the degree to which our 714 RT-qPCR assays were impacted by PCR inhibition. We posited that diluting the stool RNA 715 extracts prior to assaying for SARS-CoV-2 RNA would dilute any potential PCR inhibitors 716 J o u r n a l P r e -p r o o f derived from the stool matrix. Thus, we would expect a higher positivity rate from assaying the 717 diluted extracts. To this end, we assayed 72 clinical samples by RT-qPCR at the concentration 718 they were extracted at (1X), and at a ten-fold dilution of the same samples (0.1X). In aggregate 719 across the 4 RT-qPCR target genes, assaying the samples at 0.1X resulted in a gain of 4 positive 720 samples but a loss of 15 positive samples, likely due to viral RNA concentration falling below 721 the detection limit of the RT-qPCR assay with dilution (Data S1). Thus, the RT-qPCR analysis 722 of the stool RNA extracts likely does not exhibit a high degree of PCR inhibition. Table 1 to compare the distribution of characteristics in participants 726

reporting GI symptoms at enrollment or not. We interpreted ASDs using Cohen's guidelines (d: RdRP) and the two collection kits (OG and ZY). We augmented this with two sensitivity 735 analyses. First, we conducted a subgroup analysis that included samples from all six time-points 736 but that focused on the subset of participants who returned at least one sample during the long-737 term follow-up; we made decision to focus our primary analysis on the first three time points and 738 to supplement it with this sensitivity analysis to avoid the concern that the decision to join the 739 extended study might correlate with certain patient risk. Second, we conducted subset analyses 740 that focused on individual genes separately. In all cases, we used logistic regression models fit 741 with generalized estimating equations (GEE) 61 shedding, we fit a logistic regression to estimate the odds ratio of fecal shedding in participants 746 receiving the IFN-λ intervention versus those that received a saline placebo. We adjusted the 747 odds ratio by collection kit type (OG and ZY) and gene (E, N1, N2 and RdRP), to account for 748 systematic differences between measurements, and as well as by the patient's age and sex, 749 because randomization had been stratified by those features. 62 We included statistical interaction 750 terms between study arms and indicators for time of collection in the model to estimate the 751 difference between study arms at each time of collection. In addition to the two sensitivity 752 analyses described above, we also used a negative binomial model to assess the association 753 between the IFN-λ intervention and the total viral RNA concentration, whereas before we used 754 GEE to account for correlation within individual patients. (Fig. 3B) . However, this association failed to replicate upon closer examination 771 using several sensitivity analyses, as follows. 772 773 1) We calculated the adjusted odds ratio (aOR) that a person who received the IFN-λ intervention 774 would also be shedding viral RNA in stool at the first three time points, limiting our attention to 775 the subset of individuals who elected to participate in the extended study. Amongst these 776 participants there was no association between the intervention and fecal shedding during any of 777 the six time points (Figure S7A, B) . 778 779 2) We looked at an analysis that was restricted to just individual genes and kits. In this analysis, 780 we find that the association at the first time point is being driven entirely by samples collected in 781 the OG kit, which has previously been shown to have lower sensitivity for fecal SARS-CoV-2 782 RNA detection 11 (Data S1). Additionally, clinical appointments and symptom surveys are marked by yellow and green dots, 843

respectively. Some of these events are marked by day ranges to represent collection time frames. 844

The symptom survey at day 0 retrospectively collected symptomatology for three weeks prior to 845 enrollment using a single questionnaire. Symptom surveys at time points centered around days 846 120, 210 and 300 retrospectively collected symptomatology for one week prior to the appointment 847 using a single questionnaire at each timepoint. Collection of stool samples and their respective day 848 ranges are marked below the timeline. Subjects were asked to provide samples in the OMNIgene 849

GUT collection tube (OG) and the Zymo DNA/RNA shield fecal collection tube (ZY) at six time 850

points. B. Cohort characteristics. 120 participants were enrolled in the clinical trial. Participants 851 had a COVID-19 infection of mild to moderate severity and were between the ages of 18 and 71. 852

The age and sex distribution of the paticipants are reprented here. The x-axis separates the groups 853 by self-reported sex, and the y-axis lists age in years. Each bar represents a range of 5 years. 854 855 to moderate COVID-19 infection over a time period of 300 days from enrolment in the study. Note 874 that the ZY kits had higher overall positivity rates than the OG kits, so positivity rates in this panel 875 tend to be slightly larger than the numbers in the previous two panels, which average over kits and 876

genes. Fecal viral RNA concentration was determined using RT-qPCR with primers/probes 877 targeting the E, N1, N2, RdRP genes in the SARS-CoV-2 genome as indicated in the tab at the top 878 of each panel. The x-axis lists time point categories since enrollment. The y-axis lists the 879 percentage of participants with a given viral RNA concentration as indicated by the color scheme 880

in the stacked bar plot; dark blue refers to those with no detectable viral RNA, orange to viral RNA 881 concentrations between 0 and 1 log10 copies per µL, yellow between 1 and 2 log10 copies per µL, 882 green between 2 and 3 log10 copies per µL, and light blue over 3 log10 copies per µL. arms, as evaluated using the logistic GEE model described in the statistical methods section. The 897

x-axis marks the time point in the study: day 3 (range 0 -7), 14 (8 -21), 28 (22 -35) . The y-axis 898

indicates the percentage of participants with detectable fecal SARS-CoV-2 RNA. The blue bar 899 corresponds to participants in the placebo control arm, and the orange bar corresponds to 900 participants in the IFN-λ intervention arm. Each bar also marks the 95% confidence interval. 901

Number of participants and percentage of participants that provided a positive stool sample are 902 listed above each stacked bar in black and red fonts, respectively, and summarized in Data S1. B. 903

Odds We present these results in the overall population, as well as stratified by the presence and absence 912 of ongoing viral RNA shedding from the oropharynx (OP): A. Summary of the association between 913 viral RNA shedding and report of a given symptom, in all participants. Shedding and symptom 914 data from up to day 28 were included in this analysis. Adjusted odds ratios (aOR) for this 915 association were evaluated using the logistic GEE model described in the statistical methods 916 section, which averages over collection kits (OG and ZY), target genes (E, N1, N2, and RdRP), 917

and technical replicates, and is adjusted for age, sex, collection kit and target gene. The x-axis 918

indicates the adjusted odds ratio (aOR) for the presence of a given symptom. The y-axis lists 919 symptoms divided into those associated with the GI tract and those not associated with the GI tract. 920

The odds ratio for each symptom is indicated by the circle, and associated bars represent the 95% 921 confidence interval. 

Prevalence of gastrointestinal symptoms in coronavirus disease 2019: a meta-analysis

COVID-19: what has been learned and to be learned about the novel coronavirus disease

Gastrointestinal Manifestations of SARS-CoV-2 Infection and Virus Load in Fecal Samples From a Hong Kong Cohort: Systematic Review and Meta-analysis

Prevalence of Gastrointestinal Symptoms and Fecal Viral Shedding in Patients With Coronavirus Disease 2019: A Systematic Review and Meta-analysis

SARS-CoV-2 infection and persistence throughout the human body and brain

Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. The Lancet

AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19

Duration of Respiratory and Gastrointestinal Viral Shedding in Children With SARS-CoV-2: A Systematic Review and Synthesis of Data

Gastrointestinal symptoms and fecal nucleic acid testing of children with 2019 coronavirus disease: a systematic review and metaanalysis

The gut microbiome: a missing link in understanding the gastrointestinal manifestations of COVID-19? Cold Spring Harb Mol Case Stud 7

Standardized preservation, extraction and quantification techniques for detection of fecal SARS-CoV-2 RNA

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

The Proportion of SARS-CoV-2 Infections That Are Asymptomatic : A Systematic Review

Potential intestinal infection and faecal-oral transmission of SARS-CoV-2

Isolation of 2019-nCoV from a Stool Specimen of a Laboratory-Confirmed Case of the Coronavirus Disease 2019 (COVID-19)

Infectious SARS-CoV-2 in Feces of Patient with Severe COVID-19

Viable SARS-CoV-2 in various specimens from COVID-19 patients

Detection of SARS-CoV-2 in Different Types of Clinical Specimens

Excretion of SARS-CoV-2 through faecal specimens

Virological assessment of hospitalized patients with COVID-2019

Lack of evidence for infectious SARS-CoV-2 in feces and sewage

Evolution of antibody immunity to SARS-CoV-2

Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection

Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State: a case series

Evidence for Gastrointestinal Infection of SARS-CoV-2

Direct Evidence of Active SARS-CoV-2 Replication in the Intestine

Limited intestinal inflammation despite diarrhea, fecal viral RNA and SARS-CoV-2-specific IgA in patients with acute COVID-19

High Prevalence of Concurrent Gastrointestinal Manifestations in Patients With Severe Acute Respiratory Syndrome Coronavirus 2: Early Experience From California

Faecal calprotectin indicates intestinal inflammation in COVID-19

SARS-CoV-2 productively infects human gut enterocytes

TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes

Variable susceptibility of intestinal organoid-derived monolayers to SARS-CoV-2 infection

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Comparative Pathogenesis of Bovine and Porcine Respiratory Coronaviruses in the Animal Host Species and SARS-CoV-2 in Humans

Post-acute COVID-19 syndrome

Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial

Changes in microbiome and metabolomic profiles of fecal samples stored with stabilizing solution at room temperature: a pilot study

A method for detection of SARS-CoV-2 RNA in healthy human stool: a validation study

Applications of Digital PCR for Clinical Microbiology

SARS-CoV-2 Subgenomic RNA Kinetics in Longitudinal Clinical Samples

Bovine respiratory coronavirus

SARS-CoV-2 genomic and subgenomic RNAs in diagnostic samples are not an indicator of active replication

SARS-CoV-2 Wastewater Surveillance for Public Health Action

Making waves: Wastewater-based epidemiology for COVID-19 -approaches and challenges for surveillance and prediction

Implementation of environmental surveillance for SARS-CoV-2 virus to support public health decisions: Opportunities and challenges

How sewage could reveal true scale of coronavirus outbreak

National Wastewater Surveillance System (NWSS)

Regional specialization within the intestinal immune system

Long COVID": persistent COVID-19 symptoms in survivors managed in Lagos State

Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19

Unraveling the Mystery Surrounding Post-Acute Sequelae of COVID-19

Gastrointestinal sequelae 90 days after discharge for COVID-19

and Gemelli Against COVID-19 Post-Acute Care Study Group (2020). Persistent Symptoms in Patients After Acute COVID-19

Post-COVID syndrome: A single-center questionnaire study on 1007 participants recovered from COVID-19

High-dimensional characterization of post-acute sequelae of COVID-19

US CDC Real-Time Reverse Transcription PCR Panel for Detection of Severe Acute Respiratory Syndrome Coronavirus 2

The Digital MIQE Guidelines Update: Minimum Information for Publication of Quantitative Digital PCR Experiments for 2020

Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational Research

The effect size index: d. Statistical power analysis for the behavioral sciences

Longitudinal data analysis using generalized linear models

Stratified randomization for clinical trials

Evaluation of detection capability for clinical laboratory measurement procedures

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

CDC 2019-Novel Coronavirus (2019-nCoV) Real-Time RT-PCR Diagnostic Panel (2020). (Division of Viral Diseases

The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments

Approximately half of COVID-19 patients shed fecal RNA in the week after infection 2. 4% patients with COVID-19 shed fecal viral RNA 10 months after diagnosis

Presence of fecal SARS-CoV-2 RNA is associated with gastrointestinal symptoms

SARS-CoV-2 likely infects gastrointestinal tissue

J o u r n a l P r e -p r o o f